Company intelligence / Profile preview
Endurance Bio
San Francisco, California, United Statesendurance-bio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
T-168, the lead compound, upregulates PGC-1α, TFEB, and TRPML1 to restore mitochondrial and lysosomal function, demonstrating strong preclinical results in neurodegeneration, aging, and metabolic models; currently advancing through a placebo-controlled Phase 2 trial in Parkinson’s Disease as part of the SLEIPNIR platform, with an approved clinical trial application for ALS.
- Therapeutic areas
- ImmunologyCardiovascularNeurologyMetabolic DisordersHematologyOther
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Neuro-SysMed Centre of Excellence, Bergen, Norway (SLEIPNIR clinical trial platform)
Beyond the preview
Go deeper on Endurance Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endurance Bio.